Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment
Status:
Completed
Trial end date:
2020-11-19
Target enrollment:
Participant gender:
Summary
This multiple-center, nonrandomized, open label, parallel group, single dose study will be
conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh
Class B) hepatic impairment to evaluate the effect of hepatic impairment on the
pharmacokinetics (PK) of KBP-5074.